OncoTherapy Science (FRA:30O) Short-Term Debt: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:30O OncoTherapy Science Inc FRA:30O
51 GF Score
Price €0.08
GF Value €0.08
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Short-Term Debt?

OncoTherapy Science FRA:30O -7.06% 51 Short-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:30O with a GF Score™ of 51/100 and a GF Value™ of €0.08 (Fairly Valued). The stock has 1 warning sign investors should review.

OncoTherapy Science's Short-Term Debt for the quarter that ended in Mar. 2026 was €0.00 Mil.

OncoTherapy Science Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

OncoTherapy Science Short-Term Debt Related Terms

OncoTherapy Science Short-Term Debt Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Short-Term Debt Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OncoTherapy Science Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:30O
51GF Score
OncoTherapy Science Inc FRA:30O
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.00 Mil mean?
OncoTherapy Science (FRA:30O) has a Short-Term Debt of €0.00 Mil as of Mar. 2026.
Is OncoTherapy Science's Short-Term Debt too high?
OncoTherapy Science's current Short-Term Debt is €0.00 Mil. Overall, OncoTherapy Science has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Short-Term Debt compare to VRTX and REGN?
OncoTherapy Science's Short-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. OncoTherapy Science's current Short-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (FRA:30O) is currently considered Fairly Valued. The stock's GF Value™ is €0.08, compared to a current price of €0.08 — trading 1.3% below its estimated fair value. The current Short-Term Debt is €0.00 Mil. OncoTherapy Science's overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For OncoTherapy Science (FRA:30O), the current Short-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (FRA:30O) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be undervalued. The current stock price of €0.08 is trading 1.3% below its estimated GF Value™ of €0.08. GuruFocus considers OncoTherapy Science to be Fairly Valued.

Key valuation signals for FRA:30O:

  • Short-Term Debt: €0.00 Mil
  • GF Value™: €0.08 vs. price of €0.08 (1.3% below fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the FRA:30O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Other Exchanges 4564:Japan
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
51GF Score

Get the complete analysis for FRA:30O

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.08
Price
€0.08
GF Value